Dermamedica s.r.o. — Clinical Trial Site

10 Registered trials

4 Currently recruiting

Organisation

Dermamedica s.r.o.

Location

Nachod, Czechia

Identifier

ORG-100044737

Address

Komenskeho 420, 547 01, Czechia

Departments

42002
Dermatology
N/A
NA

Clinical trials at this site (10)

Search interface

A Study to Learn About the Study Medicine Called PF-08049820 in People With Eczema, an Itchy Skin Rash Pending

2025-522965-31-00 Atopic Dermatitis 4
Long-Term Safety Study of Deucravacitinib versus Ustekinumab in Participants with Psoriasis (PRAGMATYK) Recruiting

2023-503766-24-00 Moderate to Severe Plaque Psoriasis 11 2026-05-26
An Extension Study to Evaluate Safety, Efficacy, and Durability of Response to ESK-001 for Moderate to Severe Plaque Psoriasis (ONWARD3) Recruiting

2024-511166-36-00 Moderate to Severe Plaque Psoriasis 5 2025-06-13
A study to learn if galvokimig is safe and works in adults with moderate to severe atopic dermatitis Recruiting

2025-522578-35-00 Atopic Dermatitis 4 2026-03-30
A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of TAK-279 in Subjects with Moderate-t… Recruiting

2024-512496-12-00 Moderate to Severe Plaque Psoriasis 5 2025-04-01
Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study of Efficacy and Safety of ESK-001 for Moderate to Severe Pl… Ended

2023-507193-40-00 Moderate to Severe Plaque Psoriasis 5 2025-01-16
A Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 With a Randomized Withdrawal and Retreatment Period in Subject… Ended

2023-505842-24-00 Moderate to Severe Plaque Psoriasis 5 2024-05-07
A trial to evaluate the efficacy and safety of different doses of LEO 138559 in adults with moderate-to-severe atopic dermatitis. Ended

2022-500777-14-00 Atopic Dermatitis 4 2023-11-06
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab Monotherapy in Moderate-to-severe AD (ROCKET-Ignite) Ended

2022-501540-15-00 Atopic Dermatitis 5 2023-04-25
Long-Term PF-06651600 for the Treatment of Alopecia Areata (ALLEGROLT) Ended

2023-509801-59-00 Alopecia areata 5 2020-07-09